Regardless of subtype, diffuse gliomas of adulthood are characterized by inexorable progression through treatment. Cancer recurrence in the context of therapy is by no means unique to gliomas. For many tumors residing outside the central nervous system (CNS), tissue-based analyses are routinely employed to document the molecular and cellular features of disease recurrence. Such interventions are inconsistently applied for gliomas, however, and lack rigorous standardization when they are. While many of the reasons underlying these discrepancies reflect pragmatic realities inherent to CNS disease, the suboptimal employment of histological and molecular assessment at recurrence nevertheless represents a missed opportunity to proactively guide patient management and increase knowledge. Herein, we address this quandary by pairing a succinct description of the histological, biological, and molecular characteristics of recurrent glioma with recommendations for how to better standardize and implement quality pathological assessment into patient management. We hope this review will prompt thoughtful revision of standard operating procedures to maximize the utility of glioma re-biopsy.

Additional Metadata
Keywords glioma | adult | recurrence | pathology | pseudoprogression
Persistent URL dx.doi.org/10.1093/neuonc/noz233, hdl.handle.net/1765/128510
Journal Neuro-Oncology
Citation
Haider, A.S., van den Bent, M.J, Wen, P.Y, Vogelbaum, M.A, Chang, S.S., Canoll, P.D., … Huse, J.T. (2020). Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort. Neuro-Oncology, 22(4), 450–456. doi:10.1093/neuonc/noz233